Skip to main content
Publications
Zhou CK, Dinh J, Danysh HE , Johannes C , Gutierrez L , Schmid R, Arana A , Kaye JA, Pladevall-Vila M , Garcia-Albeniz X , Gangemi K, Yin R, Ruzafa JC, Gilsenan A , Beachler DC. Validity of claims-based algorithms to identify acute kidney injury, acute liver injury, severe complications of urinary tract infections, breast cancer, and bladder cancer among patients with type 2 diabetes: a pilot study . Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):317. doi: 10.1002/pds.4864
Dunne JL, Sutphin J, Bushman JS, Fontanals-Cirera B, Coulter JR, Hutton CT, Koralova A, Ervin CM , Mansfield C . Parent and physician preferences for screening in Type 1 diabetes (T1D) . Poster presented at the American Diabetes Association’s 79th Scientific Sessions; June 10, 2019. San Francisco, CA.
Gilbertson DT, Rothman KJ , Chertow GM, Bradbury BD, Brookhart MA, Liu L, Winkelmayer WC, Sturmer T, Monda KL, Herzog CA, Ashfaq A, Collins AJ, Wetmore JB. Excess deaths attributable to influenza-like illness in the ESRD population . J Am Soc Nephrol. 2019 Feb;30(2):346-53. doi: 10.1681/ASN.2018060581
Saigi-Morgui N , Quteineh L, Bochud PY, Crettol S, Kutalik Z, Mueller NJ, Binet I, Van Delden C, Steiger J, Mohacsi P, Dufour JF, Soccal PM, Pascual M, Eap CB, Swiss Cohort Study. Genetic and clinic predictors of new onset diabetes mellitus after transplantation . Pharmacogenomics J. 2019 Feb;19(1):53-64. doi: 10.1038/s41397-017-0001-5
Lapuerta P, Joish V, Ervin C , Evans E, Reaney M, Preblick R, De Fanti B, Castro R, DiBenedetti D . Patients with type 1 diabetes value increased glucose stability and associate it with improved well-being: exit interviews from Sotagliflozin Phase 3 study . Poster presented at the 2018 European Association for the Study of Diabetes (EASD) Conference; October 2, 2018. Berlin, Germany.
Blonde L, Raccah D, Lew E, Meyers J , Nikonova E, Ajmera M, Davis KL , Bertolini M, Guerci B. Treatment intensification in type 2 diabetes: a real world study of 2-OAD regimens, GLP-1 RAx, or basal insulin . Diabetes Ther. 2018 Jun;9(3):1169-84. doi: 10.1007/s13300-018-0429-x
Pollard DJ, Brennan A, Dixon S, Waugh N, Elliott J, Heller S, Lee E, Campbell M, Basarir H , White D, REPOSE group. Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial . BMJ Open. 2018 Apr 7;8(4):e016766. doi: 10.1136/bmjopen-2017-016766
Setji T, Hopkins TJ, Jimenez M , Manning E, Shaughnessy M, Schroeder R, Mendoza-Lattes S, Spratt S, Westover J, Aronson S. Rationalization, development, and implementation of a preoperative diabetes optimization program designed to improve perioperative outcomes and reduce cost . Diabetes Spectr. 2017 Aug;30(3):217-23.
Gutierrez L , Beachler DC, Overbeek J, McQuay L, Yin R, Kuiper J, McGrath L, Jemison J, Houben E, Lanes S, Gilsenan A , Herrings R. Characteristics of new users of dapagliflozin and other antidiabetic drugs: United States, United Kingdom, and the Netherlands . Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 28, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):128.
Blonde L, Lew E, Raccah D, Meyers J , Ajmera M, Davis K , Bertolini M, Guerci B. A real-world comparison of outcomes in patients receiving three oral antidiabetic therapies, GLP-1, or basal insulin: an analysis of electronic medical record data . Poster presented at the American Diabetes Association 77th Scientific Sessions; June 10, 2017. San Diego, CA.
Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ , Bradbury BD, Collins AJ. Epoetin alfa and outcomes in dialysis amid regulatory and payment reform . J Am Soc Nephrol. 2016 Oct;27(10):3129-38. doi: 10.1681/ASN.2015111232
Gil M, Romio S, Scotti L, Leal I, Masclee GMC, Schmedt N, Varas-Lorenzo C, Pladevall-Vila M , Smits MM, Bezemer I, Seeger JD, de Beradis G, Pecchioli S, Trifiro G, McGrogan A, Rijnbeek P, Sturkenboom M. Risk of hemorrhagic stroke associated with non-insulin blood glucose lowering drugs. Results from the SAFEGUARD project . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):428-9.
Masclee GMC, Leal I, Scotti L, De Berardis G, Bezemer I, Gil M, McGrogan A, Schmedt N, Seeger JD, Trifiro G, Pecchioli S, Pladevall-Vila M , Smits MM, Rijnbeek P, Sturkenboom M, Romio SA. Use of non-insulin blood glucose lowering drugs and the risk of acute pancreatitis . Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):246-7.
Blonde L, Kitio-Dschassi B, Guerci B, Meyers J , Berria R, Ajmera M, Nikonova E, Davis K , Bertolini M, Raccah D. A real-world comparison of longitudinal HbA1c and health care costs in patients receiving two oral antidiabetic therapies, GLP-1RAs, or basal insulin . Presented at the 76th American Diabetes Association (ADA) Scientifc Sessions; June 13, 2016. New Orleans, LA.
Blonde L, Kitio-Dschassi B, Guerci B, Meyers J , Berria R, Ajmera M, Nikonova E, Davis K , Bertolini M, Raccah D. A real-world comparison of outcomes in patients receiving two oral antidiabetic therapies, GLP-1RAs, or basal insulin: an analysis of electronic medical record data . Poster presented at the 76th American Diabetes Association (ADA) Scientifc Sessions; June 12, 2016. New Orleans, LA.